Skip to main content
OpenTrials
Completed

NCT Number: NCT02170961

Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure

this study aim to investigate the:

* association of RAAS polymorphisms and AHF * association of MMP 3 and 12 polymorphisms and AHF

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nouira Samir

Monastir, Emergency Department Monastir, Tunisia 5000, 5000, Tunisia

About this study

Heart failure can be defined as a complex clinical syndrome that results from any structural or functional disorder of the heart, with impairment of ability to fill the ventricles or eject blood. The main event of the IC is dyspnea and fatigue, which limit exercise tolerance and induces water retention.

The renin angiotensin aldosterone system governs the salt and water homeostasis in the body. Renin is a proteolytic enzyme secreted by the juxtaglomerular apparatus of the kidney (area near the glomeruli). Renin has no direct action on the organism, but that is part of the renin-angiotensin system or the renin-angiotensin-aldosterone system is known.

To date, few published studies have examined the association between the polymorphism AGT M235T * and cardiac dysfunction; and available results are contradictory. What is not known yet is the ratio of this polymorphism with the prognosis of heart failure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged more than 18 year old.
  • acute non traumatic dyspnea .

Exclusion criteria

  • ECG diagnostic for acute myocardial infarction or ischemic chest pain within the prior 24 hours
  • a history of a heart transplant, pericardial effusion, chest wall deformity suspected of causing dyspnea
  • coma, shock,MV,vasopressor drugs
  • arrhythmia serious and sustained,
  • pace maker
  • severe mitral valve disease,

Treatment and study plan

Primary outcomes

  1. mortality RAAS

    Time frame: one year

    the association between RAAS genes polymorphisms and mortality at one year average

Secondary outcomes

  1. association between RAAS polymorphism and AHF

    Time frame: at admission (an average of 1 day)

    the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the RAAS genes polymorphism is studied at patient admission for acute dyspnea.

  2. association between MMP polymorphism and AHF

    Time frame: at admission (average of 1 day)

    the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the MMP genes polymorphism is studied at patient admission for acute dyspnea.

Sponsors and collaborators

Lead sponsor

University of Monastir

Other

Registry information

Official study title

Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)

Acronym: PRA-MMP

Important dates

Study start
2013
Primary completion
2015
Study completion
2016
First posted
Jun 23, 2014
Registry last updated
Aug 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.